CAS and AstraZenec?a Agree to 5-Year SciFinder Contract
Chemical Abstracts Service (CAS), the world's authority for chemical information, has announced a landmark 5-year agreement for SciFinder, the choice for chemistry research, with AstraZeneca, a leading biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines. The long-term agreement guarantees AstraZeneca researchers access to the most accurate, comprehensive and current research, available only in SciFinder.
"SciFinder has played an important role in our research into the development of innovative, life-saving medicines," said Steve Rees, VP, Screening Sciences and Sample Management at AstraZeneca. "This partnership will support our worldwide R&D teams with the tools and knowledge they need to advance discoveries that will ultimately make a difference in the lives of patients across the globe."
An early adopter of Enterprise-Wide Pricing, AstraZeneca has relied on SciFinder to meet the needs of its researchers for nearly a decade, and this 5-year agreement is a first for SciFinder within the pharmaceutical industry. It signifies the confidence customers have in CAS as a high-quality information partner providing reliable access to the most up-to-date research in the chemical industry and beyond.
"The trust that AstraZeneca shows in SciFinder by entering into this agreement exemplifies that our content spans a multitude of scientific disciplines while maintaining the highest levels of excellence," commented Chris McCue, vice president of marketing at CAS. "Such a long-term contract sends a clear message that SciFinder is a product the biopharmaceutical industry considers essential for its research needs."
Related News
-
News Moderna to buy OriCiro Genomics in USD $85 million deal
Pharmaceutical company Moderna acquires genomics services company OriCiro Genomics, based in Tokyo, Japan, to boost mRNA therapeutics development and manufacturing portfolio. -
News New year, new prices: at least 350 drugs in USA to see price increases in January
Drugmakers such as Pfizer, GSK, BMS, AstraZeneca, and Sanofi are planning to raise prices for at least 350 unique drugs in the United States in early January. -
Sponsored Content 2023 Pharma Trend Outlook: Innovation, Resilience, and Pharma 4.0
Download our 2023 Pharma Trends Outlook report to discover the trends set to shape the pharmaceutical landscape in the new year, with expert opinions and insight from across the pharmaceutical value chain. -
News Strategic partnership between AstraZeneca and G42 Healthcare to increase pharmaceutical manufacturing in Abu Dhabi
A comprehensive, long-term partnership agreement between AstraZeneca and G42 Healthcare is set to enhance local drug manufacturing in Abu Dhabi, UAE, and bolster pharmaceutical manufacturing innovation within the country. -
News CordenPharma joins sustainability initiative to achieve Net Zero
The CDMO has joined the environmental initiative looking to align private sector companies with those aims upheld by the Paris Agreement to reduce global warming. -
News AstraZeneca acquires Neogene in shift into cell-based cancer therapies
AstraZeneca has recently announced that it will be acquiring the biotechnology company Neogene Therapeutics as part of it’s expansion into cell-based cancer treatments.
-
News A mRNA universal flu vaccine is in early stages of development
Researchers from the University of Pennsylvania have developed a universal flu vaccine using nanoparticle encapsulated mRNA. -
News Biovac partnership to increase African vaccine manufacturing capabilities
South African biopharma company Biovac signs a partnership deal with the International Vaccine Institute to develop and manufacture an oral cholera vaccine for both the African and global market.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance